Aug 2026 (Q1 FY27) — Oct 8, 2026
AngioDynamics Q1 FY27 — MedTech up 13.2%, margin expansion, new CEO named
Read the full callAngioDynamics (ANGO) earnings
- Aug 2026
- Aug 2026 (Q1 FY27)
- May 2026
AngioDynamics earnings: last reported Thu, 8 Oct 2026, for the quarter ended Aug 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 80.9 | +6.9% YoY | Quarterly, as filed | Quarter to Aug 2026 | Revenue from operations as filed. |
| Operating margin | -9.0 | +5.1 pts YoY | Operating profit / revenue | Quarter to Aug 2026 | For the quarter; a change is in percentage points. |
| Net profit | -7.1 | Quarterly, as filed | Quarter to Aug 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Guidance
What management said, and what became of it
9 targets tracked, none judged yet · 9 open · verdicts reflect calls analysed to Aug 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Adjusted EBITDA | $13 million to $16 million | May 2026 | We expect adjusted EBITDA to be in the range of $13 million to $16 million | On Track |
9 of ANGIODYNAMICS INC's 9 targets are still open. See which are on track and which have gone quiet. The 1 above are the free sample; 8 more targets are in the full ledger.
Claimed
- Revenue $80.9M, up 6.9%; MedTech $39.9M, up 13.2%, now 49% of revenue vs 47% a year ago
- Auryon $18.9M, up 14.7%, 21st consecutive quarter of double-digit growth
- NanoKnife $8.3M, up 29%; probes up 24.1% and capital up 53.5%, with record prostate procedure volumes
- Gross margin 59.4%, up 410 bps (57.8% excluding tariff refunds); adjusted EBITDA $5.0M vs $2.2M
- Adjusted loss per share $(0.04) vs $(0.10); FY27 guidance reiterated
Qualified
- Q1 operating cash use of $15.3M (seasonally largest); cash $34M
- AngioVac revenue $7.5M, down 5.9% YoY against a tougher comp
- Gross margin boosted by $1.2M tariff refunds; H2 margin expected below H1; tariff expense $0.9M
- Med Device only +1.4% and guided roughly flat; GAAP net loss $7.1M ($0.17/share)
- CEO transition: Eric Honroth succeeds Jim Clemmer Nov 2
Price
$11.39 +1.33% · +$0.15
Performance −1.3% 1Y
1Y: $11.54 on 17 Oct 2025 → $11.39. High $16.13 (31 Aug 2026), low $9.7 (7 Apr 2026).
- Previous close
- $11.24
- 52-week range
- $9.7 – $16.13
- One year
- −3.64%
Overview
- Symbol
- ANGO
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
9 targets tracked, none judged yet · 9 open · verdicts reflect calls analysed to Aug 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Adjusted EBITDA | $13 million to $16 million | May 2026 | We expect adjusted EBITDA to be in the range of $13 million to $16 million | On Track |
Claimed
- Revenue $80.9M, up 6.9%; MedTech $39.9M, up 13.2%, now 49% of revenue vs 47% a year ago
- Auryon $18.9M, up 14.7%, 21st consecutive quarter of double-digit growth
- NanoKnife $8.3M, up 29%; probes up 24.1% and capital up 53.5%, with record prostate procedure volumes
- Gross margin 59.4%, up 410 bps (57.8% excluding tariff refunds); adjusted EBITDA $5.0M vs $2.2M
- Adjusted loss per share $(0.04) vs $(0.10); FY27 guidance reiterated
Qualified
- Q1 operating cash use of $15.3M (seasonally largest); cash $34M
- AngioVac revenue $7.5M, down 5.9% YoY against a tougher comp
- Gross margin boosted by $1.2M tariff refunds; H2 margin expected below H1; tariff expense $0.9M
- Med Device only +1.4% and guided roughly flat; GAAP net loss $7.1M ($0.17/share)
- CEO transition: Eric Honroth succeeds Jim Clemmer Nov 2
The full ledger
Open ANGIODYNAMICS INC’s full ledger
A free account opens 5 company ledgers a month. All 9 tracked commitments, with each call’s wording and source.
Call summaries
May 2026 (Q4 FY26) — Jul 14, 2026
AngioDynamics, Inc. Q4 FY26 — MedTech Growth and NanoKnife Momentum Drive Profitability
Read the full callEvery analysed call
AngioDynamics earnings calls (ANGO)
Financials
What the filings say
Net profit, year on year: +35% (quarter to aug 2026 against aug 2025).
| Line item | Nov 2024 | Feb 2025 | May 2025 | Aug 2025 | Nov 2025 | Feb 2026 | May 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 73 | 72 | 80 | 76 | 79 | 78 | 87 | 81 |
| Operating profit | -11 | -10 | -6 | -11 | -6 | -13 | -10 | -7 |
| Operating margin | −15.2% | −13.8% | −7.2% | −14.1% | −7.7% | −16.5% | −11.8% | −9.0% |
| Other income | 0 | 6 | — | -0 | -0 | 5 | — | 0 |
| Profit before tax | -11 | -4 | -6 | -11 | -6 | -8 | -11 | -7 |
| Tax rate | 1.0% | 0.1% | 1.0% | −0.6% | 0.1% | −0.1% | −3.4% | 2.7% |
| Net profit | -11 | -4 | -6 | -11 | -6 | -8 | -11 | -7 |
| EPS ($ per share) | -0.26 | -0.11 | — | -0.26 | -0.15 | -0.19 | — | -0.17 |
| Line item | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 | May 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 66 | -100 | -132 | -158 | -211 | -395 | -429 | -466 |
| Total liabilities | 222 | 139 | 122 | 128 | 154 | 112 | 97 | 96 |
| Fixed assets | 24 | 28 | 37 | 45 | 44 | 36 | 32 | 27 |
| Total assets | 836 | 594 | 561 | 553 | 533 | 318 | 280 | 267 |
| Line item | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 | May 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 37 | -15 | 24 | -7 | 0 | -28 | -10 | 3 |
| Cash from investing | 83 | -63 | -14 | -19 | -10 | 124 | -10 | -6 |
| Cash from financing | 34 | -95 | -17 | 8 | 25 | -64 | -0 | 1 |
| Net cash flow | 154 | -173 | -6 | -19 | 16 | 31 | -20 | -2 |
| Capital expenditure | -3 | -7 | -5 | -4 | -4 | -3 | -4 | -3 |
| Free cash flow | 34 | -22 | 19 | -11 | -4 | -31 | -15 | 1 |
ANGO revenue by segment
Med Tech grew from 43% to 49% of revenue over the last two years.
| Segment | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Med Device | 57% | 56% | — | 53% | 55% | 52% | — | 51% | +1.4% |
| Med Tech | 43% | 44% | — | 47% | 45% | 48% | — | 49% | +13.2% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q1 FY2027 · share of revenue
- US 88% ↑ 2 pt
- Non Us 12% ↓ 2 pt
As ANGO cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
42 filings between Oct 21, 2025 and Jul 30, 2026.
Open market
decisions to buy or sellPurchases
$118.1K
1 purchase by 1 insider
Sales
$344.0K
1 sale by 1 insider
Compensation
not trading decisions- 12
- Award — granted as compensation
- 5
- Option exercise — converted options into shares
- 23
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Nighan Warren JR | — | $344.0K | Jul 30, 2026 |
| Weiss Lawrence T | $118.1K | — | Oct 21, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jul 30, 2026 | Nighan Warren JR SVP Quality and Regulatory | Sale | 23,370 | $344.0K |
| Jul 22, 2026 | Piccinini Laura SVP International | Tax withheld | 4,506 | $62.3K |
| Jul 22, 2026 | Campbell Chad Thomas SVP/GM, Vascular Access | Option exercise | 6,466 | $0 |
| Jul 22, 2026 | Campbell Chad Thomas SVP/GM, Vascular Access | Tax withheld | 2,330 | $32.2K |
| Jul 22, 2026 | Clemmer James C President and CEO | Option exercise | 52,358 | $0 |
| Jul 22, 2026 | Clemmer James C President and CEO | Tax withheld | 26,728 | $369.4K |
| Jul 22, 2026 | Trowbridge Stephen A EVP and CFO | Option exercise | 16,296 | $0 |
| Jul 22, 2026 | Trowbridge Stephen A EVP and CFO | Tax withheld | 8,319 | $115.0K |
| Jul 22, 2026 | Nighan Warren JR SVP Quality and Regulatory | Option exercise | 5,694 | $0 |
| Jul 22, 2026 | Nighan Warren JR SVP Quality and Regulatory | Tax withheld | 1,671 | $23.1K |
| Jul 22, 2026 | Piccinini Laura SVP International | Option exercise | 8,047 | $0 |
| Jul 20, 2026 | Clemmer James C President and CEO | Tax withheld | 4,223 | $57.9K |
| Jul 20, 2026 | Campbell Chad Thomas SVP/GM, Vascular Access | Tax withheld | 359 | $4.9K |
| Jul 20, 2026 | Nighan Warren JR SVP Quality and Regulatory | Tax withheld | 251 | $3.4K |
| Jul 20, 2026 | Piccinini Laura SVP International | Tax withheld | 616 | $8.4K |
| Jul 20, 2026 | Trowbridge Stephen A EVP and CFO | Tax withheld | 717 | $9.8K |
| Jul 19, 2026 | Clemmer James C President and CEO | Tax withheld | 487 | $6.6K |
| Jul 19, 2026 | Clemmer James C President and CEO | Tax withheld | 11,764 | $158.9K |
| Jul 17, 2026 | Clemmer James C President and CEO | Tax withheld | 10,649 | $143.9K |
| Jul 17, 2026 | Campbell Chad Thomas SVP/GM, Vascular Access | Tax withheld | 1,112 | $15.0K |
| Jul 17, 2026 | Nighan Warren JR SVP Quality and Regulatory | Tax withheld | 1,373 | $18.5K |
| Jul 17, 2026 | Piccinini Laura SVP International | Tax withheld | 3,074 | $41.5K |
| Jul 17, 2026 | Trowbridge Stephen A EVP and CFO | Tax withheld | 3,510 | $47.4K |
| Jul 16, 2026 | Nighan Warren JR SVP Quality and Regulatory | Tax withheld | 2,153 | $30.4K |
| Jul 16, 2026 | Trowbridge Stephen A EVP and CFO | Tax withheld | 7,840 | $110.9K |
| Jul 16, 2026 | Campbell Chad Thomas SVP/GM, Vascular Access | Tax withheld | 2,367 | $33.5K |
| Jul 16, 2026 | Clemmer James C President and CEO | Tax withheld | 18,588 | $262.8K |
| Jul 16, 2026 | Piccinini Laura SVP International | Tax withheld | 4,538 | $64.2K |
| Jul 16, 2026 | Weiss Lawrence T SVP, Chief Legal Officer | Tax withheld | 2,267 | $32.1K |
| Jul 15, 2026 | Piccinini Laura SVP International | Award | 19,860 | $0 |
| Jul 15, 2026 | Trowbridge Stephen A EVP and CFO | Award | 53,257 | $0 |
| Jul 15, 2026 | Auen Eileen O'Shea Director | Award | 11,887 | $0 |
| Jul 15, 2026 | Burgess Lorinda Director | Award | 11,887 | $0 |
| Jul 15, 2026 | Tarnoff Michael E Director | Award | 11,887 | $0 |
| Jul 15, 2026 | Nighan Warren JR SVP Quality and Regulatory | Award | 17,966 | $0 |
| Jul 15, 2026 | DONNELLY HOWARD W Director | Award | 11,887 | $0 |
| Jul 15, 2026 | Campbell Chad Thomas SVP/GM, Vascular Access | Award | 16,081 | $0 |
| Jul 15, 2026 | JOHNSON WESLEY Director | Award | 11,887 | $0 |
| Jul 15, 2026 | Weiss Lawrence T SVP, Chief Legal Officer | Award | 21,288 | $0 |
| Jul 15, 2026 | REED JAN STERN Director | Award | 11,887 | $0 |
| Jul 15, 2026 | Licitra Karen A Director | Award | 11,887 | $0 |
| Oct 21, 2025 | Weiss Lawrence T SVP, Chief Legal Officer | Purchase | 10,000 | $118.1K |
| Oct 13, 2025 | Trowbridge Stephen A EVP and CFO | Purchase | 890 | $9.9K |
| Oct 9, 2025 | Clemmer James C President and CEO | Purchase | 10,000 | $111.5K |
| Jul 21, 2025 | Nighan Warren JR SVP Quality and Regulatory | Tax withheld | 277 | $2.5K |
| Jul 21, 2025 | Trowbridge Stephen A EVP and CFO | Tax withheld | 667 | $6.0K |
| Jul 21, 2025 | Campbell Chad Thomas SVP/GM, Vascular Access | Tax withheld | 395 | $3.6K |
| Jul 20, 2025 | Campbell Chad Thomas SVP/GM, Vascular Access | Tax withheld | 359 | $3.1K |
| Jul 20, 2025 | Trowbridge Stephen A EVP and CFO | Tax withheld | 717 | $6.2K |
| Jul 20, 2025 | Clemmer James C President and CEO | Tax withheld | 2,982 | $25.9K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for ANGIODYNAMICS INC
Free account. Everything above stays public.
Write why you follow ANGIODYNAMICS INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading